Tian 2012.

Methods	Study design: parallel‐group trial Duration of follow‐up: Method of randomisation: not described Method of concealment of allocation: not described Blinding: not mentioned Power calculation: not mentioned Phases of the study: 1 (treatment phase)
Participants	Total number: 86 Country of enrolment: China Setting/location: not specified Diagnostic criteria (stable angina pectoris): not described Comorbidities: none Inclusion criteria: not described Exclusion criteria: not described
Interventions	Number of intervention groups: 2 Concomitant medications: diltiazem Excluded medications: not described Control group Intervention: no treatment Duration of intervention: not reported Ranolazine group Intervention: ranolazine (type of formulation not specified) (dosage not reported) Duration of intervention: not reported
Outcomes	Total number of outcomes: 2 (ECG total effective rate, adverse events incidence) OUTCOMES Adverse events incidence Outcome definition: not described Method and unit of measurement: absolute frequency Time points to report: not reported
Notes